Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Korro Bio, Inc.Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees.
- Prelude Therapeutics, IncorporatedPrelude Therapeutics to Participate in the Chardan Healthcare ConferencePrelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Chardan Healthcare Conference taking place in New York City on October 20, 2026.
- AlconFDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking EyesOne drop works to significantly reduce redness, with results lasting up to 12 hours 1 Lasts up to 50% longer than Lumify 1-2,* Expands Alcon's portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months GENEVA, October 16, 2026--Alcon (SI
- Nephron Pharmaceuticals Announces Leadership TransitionLou Kennedy departs from CEO role; Haywood Miller appointed Interim CEO Company remains focused on executing its transformation strategy and growth priorities while continuing to deliver safe, effective medications to customers and the patients they serve WEST COLUMBIA, S.C., October 16, 2026--Nephron
- Allegheny Health NetworkAHN Cancer Center Launches RANDY'S Trial, Funded by Community Support and Inspired by a Firefighter's LegacyClinical trial funded through The Randy & Stephanie Meyer Spread Goodness Fund seeks to expand surgical options for patients facing appendix and other peritoneal cancers — Allegheny Health Network (AHN) Cancer Center today announced the launch of...
- Robbins LLPDid You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXLShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of...
- Eight EU Capitals Want to Ban Products That Don’t Exist YetFriday 16 October, 2026 Brussels, Belgium (October 16, 2026) — We Are Innovation is urging the European Commission to reject calls for a “market freeze” on new nicotine products in the upcoming revision of the Tobacco Products Directive (TPD). The network warns that the proposal contradicts the competitiveness agenda the EU adopted after the Draghi report. On 6 October, the health ministers of the Netherlands, Belgium, Finland, France, Hungary, Latvia, Slovenia and Spain jointly asked the Commission to include a market freeze in the revised Directive. The proposal would bar any new product containing nicotine, anything with nicotine-like properties, or anything that resembles them from entering the EU market. The ministers also call for a ban on flavorings, caps on nicotine content, and standardized designs across all categories. They justify these measures as a way to prevent consumers from substituting one product for another. We Are Innovation argues that the proposal tests whether the EU has absorbed the lessons of The Future of European Competitiveness, the 2024 report by Mario Draghi. The report found that EU companies invest roughly half as much in research and innovation, as a share of GDP, as their American counterparts. It also warned that Europe is stuck in a “middle technology trap” and identified overregulation as a central cause. Between 2019 and 2024, the United States passed around 3,500 federal laws, while the EU adopted about 13,000 acts, many based on precautionary logic that hits small firms and newcomers hardest. According to We Are Innovation, the freeze would go further than any precautionary rule currently in force. Ordinary precautionary measures wait until a product exists. A market freeze would ban products before they are invented, with no evidence to evaluate, no cost-benefit analysis, and no assessment of relative risk. Novelty alone would be grounds for exclusion. By design, a rule meant to stop consumers from substituting products would stop smokers from switching away from cigarettes, the most harmful nicotine product on the market. The network points to Sweden as evidence that a different approach works. Sweden applied the same tobacco control measures as its neighbors, including high cigarette taxes, smoking bans, and health warnings. However, it also allowed adult smokers to switch to safer alternatives: first snus, then nicotine pouches from 2016. In 2022, rather than banning pouches, Sweden regulated them with age restrictions, nicotine limits, and labeling requirements. The results include: Smoking prevalence fell from 11.4% in 2012 to 3.7% in 2025, making Sweden smoke-free.Sweden records 36% fewer lung cancer deaths than the EU average.Nicotine pouches reached groups that snus never did. Among women, smoking fell from 11.2% in 2015 to 5.7% in 2024. We Are Innovation also warns that a market freeze would extend well beyond the nicotine sector. Investors in batteries, biotechnology and artificial intelligence would read it as a signal of how Europe treats new products and new entrants in general. Tetiana Rak, We Are Innovation's COO, comments, “Brussels has spent two years praising the Draghi report and promising simplification. A market freeze would ban innovations that do not yet exist, on the sole ground that they are new. If Europe wants to close its innovation gap, it cannot start by telling entrepreneurs that their products are unwelcome before they have even been invented. Swedish experience has shown that smart regulation, not prohibition, is what makes a population smoke-free.” We Are Innovation calls on the Commission to apply the method Draghi recommended and that its own Better Regulation toolbox already requires. This means quantifying a rule’s costs before adopting it, regulating nicotine products according to their relative risk, and protecting minors through age verification and enforcement rather than category bans. The network remains available to provide research and evidence to EU institutions and Member States throughout the TPD revision. ENDS ABOUT WE ARE INNOVATION We Are Innovation is a dynamic network of individuals and institutions who deeply believe in innovation's power to drive progress and solve the world's most pressing problems. With over 60 think tanks, foundations, and NGOs based worldwide, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, adopting new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are driving global transformative change. To learn more about our work, visit us at https://www.weareinnovation.global/.
- Starton Therapeutics Inc.Starton Therapeutics to Participate in Spotlight Panel at BioFuture 2026PARAMUS, N.J., October 16, 2026--Starton Therapeutics Inc. ("Starton"), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery technologies, announced today that Chief Medical Officer Dr. Jamie Oliver, Pharm.D., will participate as a panelist at BioFuture
- Edmonton Airport Expands Air Cargo Ambitions as Terracap Breaks Ground on New Airside FacilityThe 50,000-square-foot warehouse project will connect directly to Apron VIII and adds to Terracap’s existing cargo footprint at YEG. KEY TAKEAWAYS Terracap has broken ground on a new 50,000-square-foot airside cargo facility at Edmonton International Airport. The planned building fronts Apron VIII and is designed for time-sensitive goods including pharmaceuticals and perishables. Canada has committed... Read the full news article
- Myosin Therapeutics Inc.Myosin Therapeutics Invited to Present at BioFuture 2026 in New York CityMyosin Therapeutics today announced that, following its selection as a 2026–2027 National Cancer Institute (NCI) SBIR Investor Initiatives Showcase Company, it has been invited to present at BioFuture 2026, taking place October 27–28 in New...
- Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaOpus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
- GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing ShareholdersNOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA PARIS, October 16, 2026--Regulatory News: GenSight Biologics (the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and